Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum
Use
This test is useful for investigating idiopathic dysautonomic symptoms and directing a focused search for cancer in patients with idiopathic dysautonomia. It helps differentiate autoimmune dysautonomia from the effects of chemotherapy by detecting autoantibodies, which may indicate autonomic symptoms appearing during or after cancer therapy not explained by recurrent cancer or metastasis.
Special Instructions
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. When more than one evaluation is ordered under the same order number, the duplicate test will be canceled. This test should not be requested for patients who have recently received radioisotopes, due to potential assay interference. The specific waiting period before specimen collection depends on the isotope administered. Specimens will be screened for radioactivity before analysis.
Limitations
Negative results do not exclude autoimmune dysautonomia or cancer. Intravenous immunoglobulin (IVIg) treatment prior to serum collection may cause a false-positive result.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 99000-2
- 33615-6
- 72504-4
- 94694-7
- 84925-7
- 69048-7
- 48767-8
- 94287-0
- 94285-4
- 94676-4
- 101907-4
Result Turnaround Time
8-12 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
4 mL
Minimum Volume
2.5 mL
Container
Red top (preferred); Serum gel (acceptable). Submission container: Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
For optimal antibody detection, specimen collection is recommended before starting immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |